Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 12/20 | 0.51 |
| ▸ | GAA | P10253 | 12/20 | 0.51 |
| ▸ | SI | P14410 | 12/20 | 0.51 |
| ▸ | MGAM2 | Q2M2H8 | 12/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | CBFB | Q13951 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6999051 | 0.90 | CHEK1 (0.56) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL6542830 | 0.90 | GAA (0.60) | MGAMGAASIMGAM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7002030 | 0.89 | CHEK1 (0.54) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL30518181 | 0.87 | DDAH1 (0.55) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL4919548 | 0.87 | DDAH1 (0.55) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL8328058 | 0.86 | PKM (0.57) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL7461041 | 0.85 | MGAM (0.55) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL4346855 | 0.85 | MGAM (0.51) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL4062820 | 0.85 | MGAM (0.51) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL7409334 | 0.85 | MGAM (0.49) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498390-B2 | Chromium complexes and their use in olefin polymerization | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2009-03-03 | — | — | US | disclosed |
| US-7498287-B2 | Chromium complexes and their use in olefin polymerization | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080071090-A1 | Chromium complexes and their use in olefin polymerization | KACKER SMITA | 2008-03-20 | — | — | US | disclosed |
| US-20080021181-A1 | Chromium complexes and their use in olefin polymerization | KACKER SMITA | 2008-01-24 | — | — | US | disclosed |
| US-7297805-B2 | Chromium complexes and their use in olefin polymerization | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| EP-1789425-A2 | CHROMIUM COMPLEXES AND THEIR USE IN OLEFIN POLYMERIZATION | ExxonMobil Research and Engineering Company (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006012327-A2 | CHROMIUM COMPLEXES AND THEIR USE IN OLEFIN POLYMERIZATION | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20050288464-A1 | Chromium complexes and their use in olefin polymerization | EXXONMOBIL RESEARCH AND ENGINEERING COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288464-A1 | Chromium complexes and their use in olefin polymerization | CBR3, CDYL, CCRL2 | MGAM 4065/4885GAA 4618/4885SI 4577/4885 |
| US-20080071090-A1 | Chromium complexes and their use in olefin polymerization | CBR3, CDYL, CCRL2 | MGAM 4065/4885GAA 4618/4885SI 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.